Axitinib Poised To Join Pfizer's RCC Drug Portfolio In 2012
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer's second generation VEGF inhibitor axitinib for advanced renal cell carcinoma has been granted a standard, 10-month review by FDA.
You may also be interested in...
Pfizer’s Inlyta Shows Greater Efficacy In Subpopulation; Will It Be Enough For ODAC And FDA?
Pfizer's Inlyta (axitinib), proposed to treat patients with advanced renal cell carcinoma, seems to work best with patients who have undergone cytokine treatment.
Pfizer Touts Bosutinib Advantages, Debuts Hedgehog Inhibitor At ASH
Among its presentations at the American Society of Hematology meeting, Pfizer debuted Hedgehog Smoothen inhibitor PF-04449913, showing off encouraging Phase I monotherapy data in highly refractory patients. The drug would pair nicely with late-stage bosutinib to hit chronic myelogenous leukemia in two ways: through stem cells and through mature cells, Pfizer’s Rothenberg said.
Astellas Pays $125MM Up-Front To Share Rights To AVEO's Tivozanib
In a worldwide deal excluding Asia, the two companies will split both revenues and development costs 50/50 in North America and Europe.